{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-22-000141","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.213094+00:00","generated_at":"2026-06-22T03:35:40.560172+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Evolus Q3 revenue +27% to $33.9M; reiterates FY2022 guidance at top end","bullets":["Revenue $33.9M (+27% YoY); deferred $3.5M incremental due to 'Switch Your Tox' campaign, understating growth.","FY2022 revenue guidance top end $143-150M; non-GAAP opex guidance lowered to lower half of $135-140M.","Cash $65.6M; expects to fund through breakeven; operating cash use $17.1M, $3.8M less than Q2.","Added 650 new accounts (total >8,800); Evolus Rewards ~450,000 members with record 100,000 redemptions.","Launched Great Britain ops for Nuceiva; Phase II extra-strength Jeuveau enrollment completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-22-000141","json":"https://secwatch.observer/filing/0001570562-22-000141.json","markdown":"https://secwatch.observer/filing/0001570562-22-000141.md","text":"https://secwatch.observer/filing/0001570562-22-000141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/0001570562-22-000141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/eols-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:35:40.560172+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"210dfc55d15408613c1cb65fad643dd6144ee865","claim":"Evolus, Inc. reported full-year 2022 results: revenue $143 to $150 million. Guidance reaffirmed.","evidence_excerpt":"the company continues to project full-year 2022 sales at the top end of its guidance range of $143 to $150 million, which includes a minimal contribution from international markets.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/0001570562-22-000141-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2022"},{"label":"Revenue","value":"$143 to $150 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"2c0954c7263f33e9b18f3cc2720c481f14ef4f0d","claim":"Evolus, Inc. reported third quarter ended September 30, 2022 results: revenue $33.9 million.","evidence_excerpt":"Total net revenues for the third quarter of 2022 increased 27% to $33.9 million from $26.7 million in the third quarter of 2021 driven almost entirely by higher volumes of Jeuveau","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056222000141/0001570562-22-000141-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$33.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}